Traders Spotlight: Matinas BioPharma Holdings, Inc. (MTNB)

MTNB is down around 79.65% from its 12-month high of $0.58 notched on Jun 20, 2016 but is -40% above its highest point the past 12 months of $3.99 a share. Goldman Sachs Group Inc. bought a new stake in shares of Matinas BioPharma Holdings Inc (NASDAQ:MTNB) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. Noting its average daily volume at 0.47 million shares each day over the month, this signifies a pretty significant change over the norm. The analysts, on average, are forecasting a $57.88 price target, but the stock is already up 115.88% from its recent lows. The brokerage now has a buy rating on the stock. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.21. Maxim Group set a $6.00 target price on Matinas BioPharma Holdings and gave the company a “buy” rating in a report on Thursday, March 2nd.

Current levels places Matinas BioPharma Holdings, Inc.

In Healthcare sector, shares of Matinas BioPharma Holdings, Inc. Given that liquidity is king in short-term, CSX is a stock with 932.24 million shares outstanding that normally trades 2.56% of its float. The firm’s market cap is $232.15 million. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & worldwide copyright legislation.

The market experts are predicting a 180.7% rally, based on the high target price ($8) for Matinas BioPharma Holdings, Inc. shares that is likely to be hit in the 52 weeks. The firm bought 79,800 shares of the company’s stock, valued at approximately $221,000. The legal version of this news story can be read at

ILLEGAL ACTIVITY WARNING: “Hyman Charles D Takes Position in Matinas BioPharma Holdings Inc (MTNB)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. Finally, Morgan Stanley purchased a new position in shares of Matinas BioPharma Holdings during the first quarter valued at $300,000. And it remains to be seen which target price MTNB can achieve without sacrificing much as the company is holding a 375.00% gain for the past twelve months. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections.